NCT06977035 Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib
| NCT ID | NCT06977035 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sohag University |
| Condition | Rheumatoid Arthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-05-05 |
| Primary Completion | 2025-11-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-05-05 with a primary completion date of 2025-11-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). Nerve conduction studies (NCSs) are an essential tool in the evaluation of the peripheral nervous system. The sensory nerve action potential (SNAP) provides information on the sensory nerve axon and its pathway from the distal receptors in the skin to the dorsal root ganglia, while the compound muscle action potential (CMAP) is an assessment of the motor nerve fibers from their origins in the anterior horn cell to their termination along muscle fibers.
Eligibility Criteria
Inclusion Criteria: 1. Patients fulfill the 2010 ACR/EULAR classification criteria of RA 2. Age above 18 years old. 3. Patient cooperative and can answer questions Exclusion Criteria: 1. Other rheumatologic or collagen diseases. 2. Age below 18 years and above 65 years. 3. Uncooperative patients. 4. Patients with other causes of peripheral neuropathy as Diabetes mellitus.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06977035 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06977035 currently recruiting?
Yes, NCT06977035 is actively recruiting participants. Contact the research team at sara.khairy@med.sohag.edu.eg for enrollment information.
Where is the NCT06977035 trial being conducted?
This trial is being conducted at Sohag, Egypt.
Who is sponsoring the NCT06977035 clinical trial?
NCT06977035 is sponsored by Sohag University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.